drugset / Trial / NCT07569068
Neoadjuvant Tislelizumab + LM-302 + S-1 or Tislelizumab + SOX for CLDN18.2-Positive Gastric/GEJ Adenocarcinoma
RandomizedParallel-groupOpen-labelTreatment
Summary
In this study, the investigators will use Tislelizumab combined with LM-302 and S-1 versus Tislelizumab combined with SOX to treat Claudin 18.2-positive locally advanced gastric or gastroesophageal junction adenocarcinoma.
Timeline
- Start
- 2026-04-21
- Primary completion
- 2028-04-30
- Completion
- 2029-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Oxaliplatin | Small molecule | 130 mg/m2 | Intravenous |
| Subject | TPX4589 | Other / unclassified | 2 mg/kg | Intravenous |
| Comparator | S-1 | Small molecule | 40 mg | Oral |
| Comparator | S-1 | Small molecule | 50 mg | Oral |
| Comparator | S-1 | Small molecule | 60 mg | Oral |
| Comparator | Tislelizumab | Monoclonal antibody | 200 mg | Intravenous |